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Why do we need new dialysis treatment options? 
Hemodialysis (HD) is the standard renal replacement therapy for patients with end-stage kidney 
disease (ESKD), with more than 2 million patients now treated worldwide. Although significant 
advances are being made in the understanding of uremic toxins and despite major technological 
improvements over the last decades, morbidity and mortality rates remain unacceptable high. 
According to the 2013 US Renal Data System Annual data Report, adjusted rates of all-cause 
mortality are 6.5 - 7.9 times greater for dialysis patients than for age and gender matched 
individuals from the general population (http://www.usrds.org/atlas.aspx). In Europe, the 2011 
Annual Report from the European Renal Association - European Dialysis and Transplant 
Association Registry (1), shows a two-year survival probability for incident dialysis patients of 
only 71.6%. Five-year survival in UK is just marginally above that for ovarian cancer, but 
markedly less than that for colon cancer, and much lower than that for acute myocardial infarction 
or stroke (2). Therefore, there is an unmet and urgent medical need to improve the prognosis for 
ESKD patients. 
 
Why do we need convective clearance?  
Standard HD with low-permeable membranes has been shown to be an effective treatment for 
removing low-molecular weight solutes, such as urea by diffusion, but simply increasing urea 
clearance did not improve survival (3). Low permeable dialyzers are unable to effecively clear 
larger molecular weight azotemic toxins and protein-bound toxins. There is increasing evidence 
from cell culture studies, small animal models and clinical observational studies that these 
compounds cause endothelial and cardiac damage and are associated with increased 
cardiovascular mortality (4 - 6). Successful removal (7 - 10) of these larger solutes and protein-
bound compounds by hemodiafiltration (HDF) may therefore offer a viable approach to improve 
dialysis patient survival. 
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In the last few years, three large, prospective, randomized controlled trials (RCTs) have been 
conducted in different European countries to compare survival outcomes in prevalent patients 
receveing conventional HD and online post-dilution HDF (OL-HDF) (11 - 13).  
In the Convective Transport Study (CONTRAST) (11), 714 prevalent HD patients were randomly 
assigned to undergo either OL-HDF (post-dilution, target convection volume 6 liters/h) or low-
flux HD. The primary outcome was all-cause mortality. The main secondary endpoint was a 
composite of fatal and non-fatal major cardiovascular events.  After a mean follow-up of 3.0 
years, the incidence of all-cause mortality was not affected by treatment assignment. However, 
subgroup analysis suggests benefit on all-cause mortality (hazard ratio 0.57; p < 0.016) among 
those patients treated with high convection volumes (> 20 liters/treatment)  
The Turkish OL-HDF Study (12) compared the effects on morbidity and mortality outcomes for 
OL-HDF and high-flux HD. Seven hundred and eighty-two patients were randomly assigned at a 
1:1 ratio to either OL-HDF or high-flux HD. The follow-up period was 2 years. The primary 
outcome was the composite of death from any cause and non-fatal cardiovascular events. There 
was no statistically significantly difference between the two treatments. However, in a post-hoc 
analysis treatment with OL-HDF achieving  a substitution volume > 17.4 liters was associated 
with a 46% reduction ratio for overall mortality (p = 0.02) and a 71% reduction ratio for 
cardiovascular mortality (p = 0.003).  
Finally, in Catalonia (Spain), the ESHOL trial (13) assigned 906 patients either to continue HD or 
to switch to high-efficiency OL-HDF. ESHOL is the first randomized study to show a significant 
advantage for OL-HDF, reducing all-cause mortality by 30% (primary outcome, p = 0.01), 
cardiovascular mortality by 33% (secondary outcome, p = 0.06) and infection-related mortality by 
55% (secondary outcome, p = 0.03). Mean convective volumes were 23.7 liters/session; mean 
blood flow rate 387 ml/min and mean dialysis time 236 min. 
Four methods summarizing data from epidemiological studies are currently used: type I: 
qualitative summary, the narrative review article; type II: quantitative summary of published data 
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(usually called meta-analysis); type III: re-analysis of individual data based on primary studies 
(usually called pooled analysis); type IV: prospectively planned, pooled analysis of several 
studies, where pooling is already a part of the protocol (14). A meta-analysis is considered the 
highest evidence level, yet large meta-analyses on convective therapies have been published in the 
last two years, which, however, showed a discordant outcome (15 - 18). It appears that these 
analyses differ in the number of studies and patients included, the definitions of comparator and 
intervention therapy, and types of studies, varying from small observational to large prospective 
RCTs. In one meta-analysis low-flux HD was the reference therapy (17), while both low-flux and 
high-flux HD were reference therapies in three others (15, 16, 18). Considering the intervention 
arm, inclusion covered different combinations of high-flux HD, off-line HDF, hemofiltration, 
acetate-free biofiltration and post-dilution OL-HDF. Nistor et al.compared HD to HDF and 
acetate-free biofiltration (16),  Susantitaphong et al. analyzed low-flux HD in relation to high-flux 
HD and HDF (17), and Mostovaya et al considered only RCTs in which OL-HDF was compared 
to HD (15). Obviously, conclusions depend not only on data extraction and estimation of risk of 
bias, but also on the definition of convective therapies applied. In the mortality meta-analysis by 
Nistor et al. both an acetate-free biofiltration study and an off-line HDF study were included (16). 
However, these modalities can hardly be considered modern convective therapies, as the 
convection volumes of 10 - 12 liters/session achieved are similar to the amount of internal 
filtration obtained with high-flux HD and completely different from high volume HDF. After 
removing the two studies from the meta-analysis by Nistor et al. (16), the relative risk of mortality 
becomes 0.82 (95 % confidence interval 0.72 – 0.93), which appears to be a better risk estimate 
(15). A revised definition of HDF was published by the EuDial working group,  in which HDF is a 
blood purification therapy combining diffusive and convective solute transport using a high-flux 
membrane characterized by an ultrafiltration coefficient > 20 ml//h/mmHg/m2 and a sieving 
coefficient for β2 microglobulin  > 0.6; convective transport is achieved by an effective convection 
volume of at least 20% of the total blood volume processed (19). In our opinion, a statement on 
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today’s convective therapies should be based on a convection volume of at least 17 – 23 
liters/session in the online post-dilution mode. The only meta-analysis that largely fullfils this 
criterion reported  that HDF was associated with a decreased risk for all cause and cardiovascular  
mortality of 16% and 27%, respectively (15). 
Some of the problems that arise with type II meta-analysis are avoidable if individual data from all 
studies are available. Publication bias may be reduced in comparison to Type I and II meta-
analysis as even unpublished data can be included. With individual data, statistical re-analysis can 
be performed. This includes some inclusion criteria for all studies, a unified definition of 
variables, and new statistical modelling (14). The three RCTs (11 - 13) contain several potential 
risks of bias, leading to either an over- or underestimation of the true effect. An individual 
participant data meta-analytic approach might solve several methodological problems and increase 
the level of evidence for a potential effect of HDF on morbidity and mortality. In fact, this 
analysis was performed using data from CONTRAST, Turkish OL-HDF Study, ESHOL and a 
fourth as yet not published French HDF study (11 – 13, 20). The analysis was intentionally 
restricted to the above studies for two main reasons. First, to ensure high quality of the event 
adjudication, reasonable power for mortality endpoints and low risk of bias, “studies had to be 
designed to examine the effect of online HDF on mortality endpoints” (21). Secondly, not all 
convective therapies are equal (22); therefore, only RCTs comparing online HDF with HD were 
considered. This study showed that online HDF reduced the risk of all-cause mortality by 14% 
and cardiovascular mortality by 23%. The largest survival benefit was for patients receiving the 
highest delivered convection volume (> 23 liters per 1.73 m2 body surface area per session), with 
a multivariable adjusted hazard ratio of 0.78 for all-cause mortality and 0.69 for cardiovascular 
disease mortality (21). A further analysis of the same data tested different methods to standardize 
OL-HDF convection volume on all-cause and cardiovascular mortality compared to HD. All-
cause mortality was reduced when the convective dose was unstandardized or standardized to 
body surface area and total body water. Standardization by body weight or body mass index gave 
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no significant survival advantage (23). The issue of optimal convection volume for improving 
patient outcomes was recently studied in an international incident dialysis cohort treated with OL-
HDF (24). In total, 2293 patients with a minimum of 2 years of follow-up were analyzed using 
advanced statistical tools, including cubic spline analyses for determination of convection volume 
range over which a survival increase was observed. The relative survival rate of OL-HDF patients, 
adjusted for age, gender, Charlson comorbidity index, vascular access, albumin, C-reactive 
protein, and dialysis dose, was found to increase at about 55 liters/week of convection volume and 
to stay increased up to about 75 liters/week. The relative survival gain is minimal above a 
convection dose of over 75 liters/week, meaning that no additional outcome benefit could be 
expected at such very high convection volumes (24). Few studies have examined the association 
between delivered convection volume and mortality outcomes. The prospective cohort Dialysis 
Outcome Practice Patterns Sudy (DOPPS) reported that the mortality risk was 35% lower in 
European ESKD patients receiving a minimum of 15 liters/session of replacement fluid (equalling  
~ 17 liters of convection volume) than in the control population receiving standard HD, even after 
adjustment for age, comorbidities, urea clearance and local practice patterns (7). A second 
prospective observational study of more than 700 ESKD patients over a 3-year period also 
suggested that high volume HDF was associated with lower mortality risk (10). However,  a 
retrospective analysis of the entire Romanian dialysed population from the Fresenius Medical 
Care Database did not show any association between convective volume (the basal median 
convective volume was 22.2 liters/session) and mortality risk (25). This study suggested that HDF 
treatment could reduce all-cause mortality in incident and prevalent patients even after correction 
for different confounders. Interestingly, an additional survival benefit could be observed in 
incident patients (25). This issue remains still to be fully settled, since so far there are no large 
RCTs comparing HDF with HD in incident patients. 
As almost all patients enrolled into the the pooled individual participant data analysis (21, 23) 
were treated in a thrice-weekly schedule, this dose equates to ≥ 69 liters/week. One possible 
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criticism is that this dose and improved survival is confounded by selection bias, i.e. that high 
dose is only achievable in healthy patients with good functioning vascular access, with low 
mortality risk. “While extensive statistical adjustments did not materially alter the main findings, 
residual confounding may always remain” (21). Furthermore, a major limitation of the study is 
that “the included trials were not designed to assess the impact of delivered convection volume 
with OL-HDF and mortality outcomes. The analyses on convection values should therefore be 
interpreted as an observational analysis in which residual confounding cannot be excluded. A new 
RCT targeting different convection volumes would be needed to definitively examine the dose-
response effect shown in this study” (21). Finally, the analysis was better powered than the 
individual trials to study whether, compared with HD, the effect of OL-HDF differed across 
certain patient populations. In this sufficiently powered analysis, free from selection bias due to 
informative censoring, HDF was found to beneficially improve survival and reduce cardiovascular 
mortality consistently across a variety of important clinical patient subgroups (21). 
A meta-analysis is considered the highest evidence level, To further answer the question whether 
HD treatment with convective therapies improves clinical outcomes, large meta-analyses on 
convective therapies have been published in the last two years, which, however, showed a 
discordant outcome (19 - 22). It appears that these analyses differ in the number of studies and 
patients included, the definitions of comparator and intervention therapy, and types of studies, 
varying from small observational to large prospective RCTs. In one meta-analysis low-flux HD 
was the reference therapy (21), while both low-flux and high-flux HD were reference therapies in 
three others (19, 20, 22). Considering the intervention arm, inclusion covered different 
combinations of high-flux HD, off-line HDF, hemofiltration, acetate-free biofiltration and post-
dilution OL-HDF. Nistor et al.compared HD to HDF and acetate-free biofiltration (20),  
Susantitaphong et al. analyzed low-flux HD in relation to high-flux HD and HDF (21), and 
Mostovaya et al considered only RCTs in which OL-HDF was compared to HD (19). Obviously, 
conclusions depend not only on data extraction and estimation of risk of bias, but also on the 
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definition of convective therapies applied. In the mortality meta-analysis by Nistor et al. both an 
acetate-free biofiltration study and an off-line HDF study were included (20). However, these 
modalities can hardly Some of these modalities, however, cannot really be considered modern 
convective therapies, as the convection volumes of 10 - 12 liters/session achieved are similar to 
the amount of internal filtration obtained with high-flux HD and completely different from high 
volume HDF. After removing the two studies from the meta-analysis by Nistor et al. (20), the 
relative risk of mortality becomes 0.82 (95 % confidence interval 0.72 – 0.93), which appears to 
be a better risk estimate (15). A revised definition of HDF was published by the EuDial working 
group (30), in which HDF is a blood purification therapy combining diffusive and convective 
solute transport using a high-flux membrane characterized by an ultrafiltration coefficient > 20 
ml//h/mmHg/m2 and a sieving coefficient for β2 microglobulin  > 0.6; convective transport is 
achieved by an effective convection volume of at least 20% of the total blood volume processed. 
In our opinion, a statement on today’s convective therapies should be based on a convection 
volume of at least 17 – 23 liters/session in the online post-dilution mode. The only meta-analysis 
that largely fullfils this criterion reported  that HDF was associated with a decreased risk for all 
cause and cardiovascular  mortality of 16% and 27%, respectively (19). 
Taken together, the above studies (11 - 13, 15, 21, 23) support the conclusion that high volume 
post-dilution OL-HDF is associated with improved overall survival. This advantage results 
predominantly from a lower cardiovascular mortality.  
 
Why should high volume post-dilution OL-HDF be associated with improved overall 
survival? 
This crucial question generates at least two important questions: first, are the aforementioned 
RCTs (11 - 13) confounded by the favorable profile of HDF patients at entry to the study? 
Although this cannot be completely ruled out, it should be mentioned that extensive corrections 
were made in all RCTs. Secondly, what could be the underlying mechanisms? As already stated, 
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the survival  advantage results predominantly from lower cardiovascular mortality. According to 
the 2015 US Renal Data System Annual data Report, cardiovascular mortality of US ESKD 
patients in 2013 accounted for 53.1% of deaths: the main causes were arrhythmia/cardiac arrest 
(37.0%), acute myocardial infarction and atherosclerotic heart diseases (6.7%), congestive heart 
failure (5.8%) and cerebrovascular accidents (3.1%) (http://www.usrds.org/atlas.aspx). In theory, 
both a decrease in the incidence of heart failure, ischemic heart disease, sudden cardiac death and 
stroke may play a role. Interestingly, in ESHOL (13) a reduction in stroke was found, while the 
incidence of heart failure and ischemic heart disease was similar. None of the three recent 
published RCTs (11 - 13) found a difference in sudden cardiac death between HD and HDF. 
Echocardiographic studies reported in the literature indicate that the functional and structural 
deterioration of the left ventricle over time in HD patients could be  mitigated or even prevented  
in HDF: analysis of a large subset of the CONTRAST cohort (11) revealed that, whereas both left 
ventricle mass and ejection fraction deteriorated over time in the HD patients, these parameters 
remained stable in the HDF group (26). Moreover, a recent RCT reported  that high volume HDF 
(> 22 liters/session) prevented the endothelial dysfunction and stiffening of conduit arteries that 
was observed in HD patients (27). Thus, the advantage of high volume post-dilution OL-HDF 
could be possibly due to better preservation of left ventricle mass and function. 
Improved stability of intra-dialytic blood pressure could also potentially contribute to the 
beneficial effect of high volume OL-HDF on survival. Intra-dialytic hypotension (IHD) is a 
common problem during  HD, and has been related to cardiac stunning, bowel ischemia and brain 
hypoperfusion. The occurrence of IDH was not documented in the primary CONTRAST paper 
(11); it was a secondary outcome in the Turkish study  (12), but results were not described in their 
primary paper; in the ESHOL trial (13) IDH was monitored and the results were reported: in the 
HDF group, there were 679 episodes of IDH per 100 patient-years vs. 938 episodes of IDH with 
HD, a difference which was highly statistically significant. Observational studies now suggest that 
IDH is strongly associated with poor outcomes, and especially poor cardiovascular outcomes. 
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Interestingly, treatment with cooled dialysate reduces IDH, HD-induced brain injury (28) and 
improves cardiovascular survival (29). Two large RCTs reported that blood pressure stability 
during HDF was superior to HD (13, 30), but not but not a third one (12). However, when cooled 
dialysate was used both in HDF and HD, hemodynamic changes, as measured as blood pressure, 
blood volume, cardiac output and microcirculation, did not differ (31). Hence, it appears that 
intradialytic hemodynamic stability is better preserved during HDF than during standard HD, but 
analogous to cooled-dialysate HD. Unfortunalely, none of the three recent RCTs (11 - 13) on high 
volume OL-HDF reported dialysate temperature. Temperature balance studies would suggest that 
if the cause of slight extracorporeal cooling with post-dilution HDF is due to the slightly lower 
temperature of the substitution fluid stream, then all other things being equal, increasing the 
substitution fluid infusion flow rate should result in more extracorporeal circuit cooling (32).   
There is no compelling evidence to-date that high volume post-dilution OL-HDF reduces 
mortality by improvements in traditional (such as high blood pressure and cholesterol levels) and 
non-traditional risk factors (such as reducing azotemic toxins or reducing the bio-incompatibility 
of the extra-corporeal system). In terms of solute removal, neither Kt/Vurea nor β2 microglobulin 
were associated with survival. None of the meta-analyses or RCTs reported a decline in other 
causes of death, such as withdrawal from dialysis or malignancies. Infectious complications are 
usually linked to bacterial spread from vascular access, particularly in the case of central venous 
catheters, and respiratory infections. Whereas no overall difference was observed in CONTRAST 
(11), infection-related mortality in ESHOL (13) was lowest in HDF patients. Whether this 
reduction in infection resulted from a lower central venous catheter usage in the HDF group (7% 
in the HDF group vs. HD 13%) or from the high convection volumes applied remains to be 
established. 
 
Why choose high volume post-dilution OL-HDF? 
Significant advances have been made in the understanding of uremic toxins and major 
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technological improvements have been achieved over the last decades. High volume post-dilution 
OL-HDF appears to be one of the most important technological improvements of the last decade. 
A revised definition of HDF was published by the EuDial working group (30), in which HDF is a 
blood purification therapy combining diffusive and convective solute transport using a high-flux 
membrane characterized by an ultrafiltration coefficient > 20 ml//h/mmHg/m2 and a sieving 
coefficient for β2 microglobulin  > 0.6; convective transport is achieved by an effective convection 
volume of at least 20% of the total blood volume processed. Recommendations to achieve the 
optimal high volume post-dilution OL-HDF convection dose are reported in Table 1.  
Why choose high volume post-dilution OL-HDF? Because it is associated with improved overall 
survival. This advantage results predominantly from reduced cardiovascular mortality, possibly 
due to better preservation of left ventricle mass and function. Improved intra-dialytic blood 
pressure stability may additionally contribute to the beneficial effect of high volume post-dilution 
OL-HDF on survival. The improved patient survival associated with high volume post-dilution 
OL-HDF is not restricted to selected patient groups, depending upon  age, comorbidity or dialysis 
vintage. There is no compelling evidence to-date that high volume post-dilution OL-HDF reduces 
mortality by improvements in traditional and non-traditional cardiovascular risk factors. There are 
still no studies nor case reports published describing  adverse clinical outcomes in more than  20 
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